Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 2: Long-Term Extension Study of JNJ-77242113 in Moderate-to-Severe Plaque Psoriasis
NCT05364554Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 2 trial of icotrokinra in plaque psoriasis (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Who Achieved Greater Than or Equal to 75% Improvement From Baseline in Psoriasis Area Severity Index Score at 36 weeks. Started Jun 2022; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05364554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364554.